

With their MPTxpress Technology surpassing the Conventional Fermentation Process in the Production of Recombinant Biologics and having the potential to become the Standard Production Protocol for Bacterial Expression in this \$2 Billion Market, MicoProtein Technologies, Inc. is well Position for Growth

Biotechnology

MicroProtein Technologies Inc.
17745 Metcalf Ave
Stilwell, KS 66085
913-851-0877
www.mptbiotechs.com



Vinod Pandiripally
CEO

BIO:

MicroProtein Technologies, Inc (MPT). We at MicroProtein Technologies, Inc. are pleased to announce the publication of "CEOCFO Magazine" interview with MicroProtein's Founder & President, Vinod K. Pandiripally, Ph.D.

About

MicroProtein Technologies Inc.

MicroProtein Technologies Inc. (MPT) is a privately owned dynamic and young biotechnology company. MPT is the first company to produce recombinant biologics on an industrial scale without employing the conventional fermentation process. Utilizing

its proprietary process (MPTxpress), MPT has managed to design and develop a robust solid media based platform process, which surpasses conventional fermentation process as a reliable way to produce recombinant biologics. MPTxpress has the added advantage of higher yields, repeatable, reliable, lower production costs, reduced culture volumes, minimal upstream and down-stream processing, reduced wastewater, and drastically eliminates the need of expensive and often unreliable equipment. The MPTxpress process is scalable from R&D studies to industrial production. The bacterial expression system remains the most preferred choice for recombinant expression in the industry today due to its versatility and capability to produce homologous, as well as heterologous proteins. It is therefore, necessary to have a production platform that can circumvent the challenges posed by fermenters and liquid media while increasing the current specific yield ratio. MPTxpress has achieved all these objectives and therefore, has the potential to become the standard production protocol for bacterial expression in this \$2 billion market.

The MPTxpress platform is protected under patents filed with the United States Patent and Trademark Office, being the first technology of its kind to provide such a high-yield percentage with efficacy as well as truly environmentally friendly features.

Interview conducted by:
Lynn Fosse, Senior Editor

CEOCFO: Mr. Pandiripally, MicroProtein Technologies is a pioneer in the field of biotechnology. Would you explain what you are doing and how it differs from other approaches?

Mr. Pandiripally: Instead of conventional liquid fermentation, we use substantially solid media fermentation that has never been done for bacteria such as E.coli. We basically shifted the process from liquid based fermentation to substantially solid media. In doing so, we eliminated the use of expensive and often unreliable equipment and reduced the upstream process to one day. MPTxpress is a robust tailor made process (i.e. no re-optimization) and scalable from small to industrial scale.

Specific yield of recombinant protein per gram of cell paste is the highest in the industry, thus leads to very efficient downstream process. Recombinant biologics produced through this process, is more pure, more stable. Right now, we produce Protein A, Protein G, Protein A/G combination and a number of other therapeutic proteins to validate MPTxpress process. We currently have customers and we are trending towards increasing our customer base by multifold from 2013 onwards.

CEOCFO: Has this method been tried in the past?

Mr. Pandiripally: Yes. It has been tried in the past but it did not work.

CEOCFO: What is it that you have figured out that others missed?

Mr. Pandiripally: We patented the process. Basically, a subtle combina-

tion of host, plasmids, media and temperature has made the process to work.

CEOCFO: Who is using your services today?

Mr. Pandiripally: We produce recombinant biologics such as Proteins, Enzyme, and Plasmid DNA on R&D scale to industrial scale. MicroProtein Technologies Inc. (MPT) is a pioneer in the field of biotechnology. Using patented MPTxpress technology, we lead the industry in the production of recombinant biologics (proteins/enzymes/plasmid DNA) for use in biotechnology, diagnostics, biopharmaceuticals, veterinary medicine, and non-clinical academic purposes.

CEOCFO: Are there particular industry segments that make more use of your services than others?

Mr. Pandiripally: Our customer base is concentrated in major bioprocessing vendors and reagents companies. We should be getting certification for ISO 9001:2008(E) before 2013, and we are also working towards getting cGMP facility ready in one or two years.

CEOCFO: Is the industry aware of the difference in what you do?

Mr. Pandiripally: Yes.

CEOCFO: How do you reach potential customers?

Mr. Pandiripally: We reach customers/clients via internet (www.mptbiotech.com), meetings, seminars and word of mouth. MicroProtein Technologies Inc: Recipient of the 2012 North American Recombinant Protein Expression Systems Technology Innovation Award.

CEOCFO: Has that garnered much attention for you?

Mr. Pandiripally: Yes. We are updating our website on or before December 2012.

CEOCFO: Are you able to handle a large influx of new customers if that comes your way?

Mr. Pandiripally: Yes we are. We are gearing towards that. We are a small

business. We do not have many resources, but we are gearing towards a larger customer base from 2013.

CEOCFO: Do you have the facilities and the personnel?

Mr. Pandiripally: Yes we do and we are also expanding to meet business potential. We are also going for ISO 9000 certification by the end of this month or next month.

CEOCFO: Does MicroProtein Technology have all of the funding that it needs?

Mr. Pandiripally: Tentatively Yes.

CEOCFO: So you are good to go there?

Mr. Pandiripally: I am optimistic.

“The bacterial expression system remains the most preferred choice for recombinant expression in the industry today due to its versatility and capability to produce homologous, as well as heterologous proteins. It is therefore, necessary to have a production platform that can circumvent the challenges posed by fermenters and liquid media while increasing the current yield ratio. MPTxpress has achieved all these objectives and therefore, has the potential to become the standard production protocol for bacterial expression in this \$2 billion market.”- Vinod Pandiripally

CEOCFO: Do you see other companies trying to jump on the bandwagon with the approach that you have developed?

Mr. Pandiripally: It is difficult to measure that. People do ask me such questions some time.

CEOCFO: Are your customers primarily in the US now?

Mr. Pandiripally: Currently our customers are in US, and few potential customers from Europe.

CEOCFO: Are you looking to increase the geographic distribution as well? Are you ready to grow and get going?

Mr. Pandiripally: Yes.

CEOCFO: Are you ready to grow and get going?

Mr. Pandiripally: We are increasing our production capacity to meet potential customer demand.

CEOCFO: What are some of the most important things that you have learned in your background that you are able to bring to the table in commercializing the current company and products?

Mr. Pandiripally: Learn to be patience, persist and never give up. It is frustrating sometimes; but we are making process from securing finance, and constantly tweaking the process. However, most of them did work out up to our expectations and securing finance was a hard nut to crack.

CEOCFO: Why should MicroProtein Technology stand out for investors and people in the business community?

Mr. Pandiripally: We are unique. We are “out of the box”. Our products are superior when compared to competitor’s products from major suppliers. For example, Protein A, Protein G and Protein AG chimeric proteins produced by us are 3-5 times more active when compared to competitors’ products and most importantly we produce them cost-effectively. In recombinant biologics manufacturing, cost and operational excellence is a big issue and we happy and proud that we successfully produce more value with fewer resources.

The bacterial expression system remains the most preferred choice for recombinant expression in the industry today due to its versatility and capability to produce homologous, as well as heterologous proteins. It is therefore, necessary to have a production platform that can circumvent the challenges posed by fermenters and liquid media while increasing the current yield ratio. MPTxpress has achieved all these objectives and therefore, has the potential to become the standard production protocol for bacterial expression in this \$2 billion market.